SYSTEMIC THIOSULFATE PROTECTION DURING FRACTIONATED REGIONAL NITROGEN MUSTARD THERAPY.
D035843:Biomedical Research; D002277:Carcinoma; D002294:Carcinoma, Squamous Cell; D004285:Dogs; D005853:Geriatrics; D007263:Infusions, Parenteral; D007269:Injections, Intra-Arterial; D007275:Injections, Intravenous; D007970:Leukopenia; D008113:Liver Neoplasms; D008466:Mechlorethamine; D008545:Melanoma; D009369:Neoplasms / Q000628:therapy*; D009588:Nitrogen Mustard Compounds; D012516:Osteosarcoma; D012106:Research; D012509:Sarcoma; D012514:Sarcoma, Kaposi; D013848:Thigh; D013885:Thiosulfates; D014116:Toxicology
D009588:Nitrogen Mustard Compounds; D013885:Thiosulfates; D008466:Mechlorethamine
CARCINOMA, EPIDERMOID; CLINICAL RESEARCH; DOGS; EXPERIMENTAL LAB STUDY; GERIATRICS; INFUSIONS, PARENTERAL; INJECTIONS, INTRA-ARTERIAL; INJECTIONS, INTRAVENOUS; LEUKOPENIA; LIVER NEOPLASMS; MECHLORETHAMINE; MELANOMA; NEOPLASM THERAPY; NITROGEN MUSTARD COMPOUNDS; SARCOMA, KAPOSI'S; SARCOMA, OSTEOGENIC; THIGH; THIOSULFATES; TOXICOLOGIC REPORT